Stock IMNM IMMUNOME, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Immunome, Inc.

Equities

IMNM

US45257U1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
17.18 USD -1.15% Intraday chart for Immunome, Inc. -18.27% +60.56%
Apr. 15 Guggenheim Starts Immunome With Buy Rating, $35 Price Target MT
Apr. 01 Wedbush Adjusts Immunome's Price Target to $33 From $27, Maintains Outperform Rating MT

Evolution of the average Target Price on Immunome, Inc.

Price target over the last 5 years

History of analyst recommendation changes

591330cea69dd2892.8Bo9rqMS9hjp_UY7lnnWvvkY95ODQ6nV5yER4rAahdA.uWh6g_FHsVWInHZT_zah5rAgksT0dOayqhVyscNP6aq3WQmW_HuTX5meLQ~8602f072145708380e46677dae01e2b1

Analyst Recommendations on Immunome, Inc.

Guggenheim Starts Immunome With Buy Rating, $35 Price Target MT
Wedbush Adjusts Immunome's Price Target to $33 From $27, Maintains Outperform Rating MT
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating MT
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating MT
Immunome Shares Rise After Wedbush Starts Coverage With outperform Rating MT
Wedbush Starts Immunome With Outperform Rating, $12 Price Target; Has Positive View for Early-Stage Pipeline of Targeted Cancer Therapies MT
Chardan Cuts Price Target on Immunome to $8 From $9, Maintains Buy Rating MT
Cantor Fitzgerald Initiates Immunome's Coverage With Overweight Rating, Sets Price Target at $8 MT
Chardan Adjusts Immunome's Price Target to $9 From $16, Citing IMM-BCP-01 Launch Expectations, Stock Dilution From Future Capital Raises; Buy Rating Kept MT
Cantor Fitzgerald Starts Immunome at Overweight with $35 Price Target MT
IMMUNOME : Chardan Adjusts Price Target on Immunome to $21 From $18 on Q2 Update, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
17.18 USD
Average target price
35.33 USD
Spread / Average Target
+105.67%
High Price Target
38 USD
Spread / Highest target
+121.19%
Low Price Target
33 USD
Spread / Lowest Target
+92.08%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Immunome, Inc.

Guggenheim
Wedbush
Chardan Research
Cantor Fitzgerald
Chardan

Ratings for Immunome, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IMNM Stock
  4. Consensus Immunome, Inc.